iBio, Inc. has announced the initiation of a first-in-human clinical trial for IBIO-600, a long-acting anti-myostatin monoclonal antibody aimed at preserving muscle mass and improving body composition in overweight and obese adults. Following the acknowledgment of a Clinical Trial Notification (CTN) from Australia’s Therapeutic Goods Administration (TGA) and ethics approval from a Human Research Ethics Committee (HREC), the company expects to dose the first participant in the second quarter of 2026. This trial will be a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBIO-600.

The significance of IBIO-600 lies in its potential to address the unmet need for therapies that mitigate muscle loss associated with obesity and weight reduction, particularly in the context of existing GLP-1 therapies. Preclinical studies in non-human primates have shown promising results, including sustained pharmacologic activity and an extended half-life of 40-52 days post-administration. Moreover, these studies indicated dose-dependent increases in lean mass of up to 5.1%, alongside reductions in fat mass, suggesting that IBIO-600 could play a crucial role in enhancing body composition and overall healthspan.

The advancement of IBIO-600 into clinical development represents a pivotal shift in the approach to treating obesity-related muscle loss. With its infrequent dosing regimen, potentially requiring administration only two to four times per year, IBIO-600 could streamline treatment protocols and improve patient adherence. This development not only underscores the capabilities of iBio’s AI-integrated discovery platform but also highlights a new avenue for research focused on the intersection of muscle preservation and metabolic health, potentially influencing future drug development timelines and strategies in the field of longevity and healthspan research.

Source: globenewswire.com